Chiusura precedente | 1,5000 |
Aperto | N/D |
Denaro | 0,0000 |
Domanda | 0,0000 |
Prezzo d'esercizio | 7,50 |
Scadenza | 2025-03-21 |
Min-Max giorno | 1,5000 - 1,5000 |
Contratto - Min-Max | N/D |
Volume | |
Open Interest | 2 |
Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief Financial OfficerPreliminary, unaudited third quarter 2023 revenue expected to be approximately $17.6 millionManagement to host conference call on October 30, 2023 to discuss third quarter 2023 financial results REDWOOD CITY, Calif., Oct. 10, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally in
REDWOOD CITY, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx”) a global leader in minimally invasive treatments for severe lung disease, today announced the company will be participating in two upcoming investor conferences. Pulmonx management is scheduled to participate in a fireside chat at the 2023 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2023, at 11:15am PT / 2:15pm ET. Interested parties may access a live and archived web
REDWOOD CITY, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the "Company"), a global leader in minimally invasive treatments for lung disease, today reported financial results for the second quarter of 2023 ended June 30, 2023. Recent Highlights Achieved record worldwide revenue of $17.2 million in the second quarter of 2023, a 23% increase over the same period last yearDelivered a new high of $11.0 million in U.S. revenue in the second quarter of 202